Stopping Ibrutinib after 6 Years of Continuous Exposure Results in Decreased or Stable CLL Levels for at Least a Year in Most Patients, Providing Further Support for the STATIC Trial Evaluating Intermittent BTKi Treatment
LEUKEMIA & LYMPHOMA（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要